Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APRE Aprea Therapeutics, Inc.

Market Closed 10-16 16:00:00 EDT

0.5842

-0.0334

-5.41%

盘后0.6206

+0.0364+6.23%

19:04 EDT

High0.6580	Low0.5729	Vol160.10K
Open0.6580	D1 Closing0.6176	Amplitude13.78%
Mkt Cap7.36M	Tradable Cap4.62M	Total Shares12.59M
T/O96.67K	T/O Rate2.02%	Tradable Shares7.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.5842,"timestamp":1792180800000,"preClose":0.6176,"halted":0,"volume":160104,"hourTrading":{"tag":"盘后","latestPrice":0.6206,"preClose":0.5842,"latestTime":"19:04 EDT","volume":3256,"amount":2068.3927,"timestamp":1792191870351,"change":0.0364,"changeRate":0.062307,"amplitude":0.059911},"delay":0,"changeRate":-0.054080310880828986,"floatShares":7910100,"shares":12591099,"eps":-0.94,"marketStatus":"Market Closed","change":-0.0334,"latestTime":"10-16 16:00:00 EDT","open":0.658,"high":0.658,"low":0.5729,"amount":96669.154134,"amplitude":0.137791,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.94,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":7,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.6176,"preHourTrading":{"tag":"盘前","latestPrice":0.62,"preClose":0.6176,"latestTime":"08:53 EDT","volume":7,"amount":4.48089985,"timestamp":1792155209932,"change":0.0024,"changeRate":0.003886,"amplitude":0.145725},"postHourTrading":{"tag":"盘后","latestPrice":0.6206,"preClose":0.5842,"latestTime":"19:04 EDT","volume":3256,"amount":2068.3927,"timestamp":1792191870351,"change":0.0364,"changeRate":0.062307,"amplitude":0.059911},"volumeRatio":1.7183445049434638,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE","defaultTab":"news","newsList":[{"id":"2675594724","title":"Aprea Therapeutics Hosts Virtual Panel on WEE1 Inhibition in Precision Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2675594724","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675594724?lang=en_us&edition=fundamental","pubTime":"2026-10-16 20:31","pubTimestamp":1792153861,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Hosts Virtual Panel on WEE1 Inhibition in Precision OncologyAprea Therapeutics will host a virtual panel on WEE1 inhibition in precision oncology on Oct. 20, 2026, at 11 a.m. ET.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDL1Z9YJn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014005.SGD","BK4139","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BCDF","LU2210150020.SGD","BK4585","IE00BQXX3C00.GBP","IE00BKPKM429.USD","APRE","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","NDAQ","SG9999014021.USD","IE00BN0W2V16.EUR","BK4588","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675274383","title":"Aprea Therapeutics Initiated at Buy by Ladenburg Thalmann","url":"https://stock-news.laohu8.com/highlight/detail?id=2675274383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675274383?lang=en_us&edition=fundamental","pubTime":"2026-10-15 05:01","pubTimestamp":1792011660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APRE/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","APRE","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675345730","title":"Aprea Therapeutics initiated with a Buy at Ladenburg","url":"https://stock-news.laohu8.com/highlight/detail?id=2675345730","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675345730?lang=en_us&edition=fundamental","pubTime":"2026-10-14 18:50","pubTimestamp":1791975045,"startTime":"0","endTime":"0","summary":"Ladenburg initiated coverage of Aprea Therapeutics (APRE) with a Buy rating and $2 price target Published first on TheFly – the ultimate source for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-initiated-with-a-buy-at-ladenburg-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aprea-therapeutics-initiated-with-a-buy-at-ladenburg-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","APRE","BK4139","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673707573","title":"Aprea Therapeutics CEO to Join Maxim Growth Summit Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2673707573","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673707573?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:32","pubTimestamp":1791203551,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics CEO to join Maxim Growth Summit fireside chatAprea Therapeutics CEO Oren Gilad will join a fireside chat at the 2026 Maxim Growth Summit on Oct. 14 at 9 a.m. ET.The session is sched","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDLbKxhfZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BCDF","LU2210150020.SGD","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","BK4139","IE00BKPKM429.USD","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","IE00BQXX3C00.GBP","SG9999014039.USD","SG9999014005.SGD","BK4585","APRE","IE00BN0W2T93.GBP","NDAQ","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4588","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666593841","title":"Aprea Therapeutics CEO to Present at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666593841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666593841?lang=en_us&edition=fundamental","pubTime":"2026-09-10 20:05","pubTimestamp":1789041931,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics CEO to present at H.C. Wainwright Global Investment ConferenceAprea Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 14-16, 2026.Ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL485QPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","BK4112","SG9999014005.SGD","IE00BN0W2T93.GBP","APRE","BCDF","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4585","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BQXX3C00.GBP","SG9999014021.USD","BK4139","BK4588","IE00BQXX3F31.USD","LU0314104364.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167963","title":"Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167963","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167963?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:25","pubTimestamp":1786652704,"startTime":"0","endTime":"0","summary":"Ensysce Biosciences Q2 net loss widens on higher R&D costsOverviewUS biotech firm's Q2 net loss widened yr/yr on higher R&D expensesCompany completed Cy Biopharma acquisition post-quarter, adding CY20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KOD","ENSC","APRE","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156740","title":"Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156740?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:16","pubTimestamp":1786619767,"startTime":"0","endTime":"0","summary":"Pyxis Oncology Q2 loss widens on increased administrative costsOverviewUS cancer therapeutics developer's Q2 net loss widened yr/yr as operating expenses roseCompany completed $50 mln private placemen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","PYXS","IMNM","CRDF","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659990044","title":"Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659990044","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659990044?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:22","pubTimestamp":1786566165,"startTime":"0","endTime":"0","summary":"Longeveron Q2 net loss widens on higher legal, clinical trial costsOverviewUS biotech firm's Q2 revenue fell 10% yr/yr, mainly due to lower contract manufacturing incomeNet loss for Q2 widened 22% yr/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44911Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","LGVN","BK4139","OLMA","BK4505","SPRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658088309","title":"Aprea Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658088309","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658088309?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:24","pubTimestamp":1786541089,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAprea Therapeutics IncAPRE.OQreported a quarterly adjusted loss of 7 cents per share for the quarter ended June 3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4491BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970424","title":"LiveWorld Q2 Net Loss Widens on Higher Operating Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970424","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970424?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:10","pubTimestamp":1786540207,"startTime":"0","endTime":"0","summary":"LiveWorld Q2 net loss widens on higher operating costsOverviewAI-powered intelligence systems firm's Q2 revenue grew 9% yr/yr, driven by healthcare segmentCompany posted Q2 net loss from operations of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SMWB","BK4139","APRE","PHUN","BK4023","LVWD","BK4608","BK4516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658977651","title":"Aprea Therapeutics Q2 EPS USD -0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2658977651","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658977651?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:31","pubTimestamp":1786537864,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXH9GCNT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658497759","title":"Aprea Therapeutics Announces Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658497759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658497759?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:30","pubTimestamp":1786537802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUAN9FHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951980","title":"Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951980","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951980?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:33","pubTimestamp":1786393980,"startTime":"0","endTime":"0","summary":"HEADLINESBarrick Mining Settles Newmont Nevada Dispute for $1.95 Billion, Clearing Way to List its Gold AssetsBarrick Mining has settled a long-standing dispute with rival Newmont over their Nevada op","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEMS","ACCS","BK4179","LEGN","GHI","BWEN","HBIO","NVRI","MIDD","IMUX","PESI","STIM","VSTS","CANC","LU0154236417.USD","LU0240877869.USD","LVWD","BK4167","KLXE","IMNN","IE00B3S45H60.SGD","MEDI","TCRX","MASS","BSIN","REFI","RXT","AMTM","ARMK","TNGX","SLSN","BK4109","APRE","AVXL","JBI","BK4123","BK4127","BK4175","BK4023","DOMH","FLOC","CRIS","OBIO","SG9999001440.SGD","SLAB","VERA","WHF","SYPR","CAH","DRIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657476196","title":"Aprea Therapeutics Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657476196","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657476196?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:48","pubTimestamp":1786117685,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics Inc <APRE.OQ> expected to post a loss of23cents a share - Earnings PreviewAprea Therapeutics IncAPRE.OQAPRE.Ois expected to  show a rise in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683675","title":"Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683675","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657683675?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:30","pubTimestamp":1785861019,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc. ($APRE) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. (APRE) has completed a Phase 1/2a st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apreas-atrn-119-trial-completion-what-it-means-for-apre-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apreas-atrn-119-trial-completion-what-it-means-for-apre-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","APRE","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655436872","title":"Aprea Therapeutics Targets Q4 2026 Clinical Data Readout for Apr-1051 Phase 1 Acesot-1051 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2655436872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655436872?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:10","pubTimestamp":1785413414,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics targets Q4 2026 clinical data readout for APR-1051 Phase 1 ACESOT-1051 trialAprea outlined plans to accelerate enrollment in its Phase 1 ACESOT-1051 dose-escalation trial of WEE1 in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL6FQZ2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","SG9999014013.SGD","NDAQ","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","BK4588","SG9999014039.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","IE00BGHQF748.EUR","BCDF","IE00BN0W2V16.EUR","LU2210149790.SGD","BK4139","APRE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874761","title":"Aprea Therapeutics - Acesot-1051 Enrollment Accelerating to 6-10 Patients Per Month by Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874761?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874750","title":"Aprea Therapeutics - Dose Escalation and Backfill Expansion Expected to Complete in Q2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874750?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655874721","title":"Aprea Therapeutics - to Enroll at Least 50 Patients with Usc or Cyclin E-Overexpressing Proc","url":"https://stock-news.laohu8.com/highlight/detail?id=2655874721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655874721?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655747518","title":"Aprea Therapeutics Provides Acesot-1051 Program Update for Wee1 Inhibitor Apr-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655747518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655747518?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JHH3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":-0.0334},{"period":"1month","weight":-0.2003},{"period":"3month","weight":-0.1766},{"period":"6month","weight":-0.4158},{"period":"1year","weight":-0.6206},{"period":"ytd","weight":-0.3151}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.06034},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.033286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.111168},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.117728},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.094212},{"month":6,"riseRate":0.285714,"avgChangeRate":0.005319},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.070517},{"month":8,"riseRate":0.428571,"avgChangeRate":0.036999},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.054211},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.019697},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.053133}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aprea Therapeutics, Inc.(APRE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}